The Use of Psychotropic Drugs in Epilepsy: What Every Neurologist Should Know

ABSTRACT

Psychiatric disorders, such as mood, anxiety, attention deficit, and psychotic disorders, are among the most frequent comorbidities experienced by patients with epilepsy. While these psychiatric disorders have typically been considered as one of its complications, there is increasing evidence of a bidirectional relationship between the seizure disorder and mood and ADHD. Indeed, not only are patients with epilepsy at greater risk of developing these two disorders, but patients with mood and attention deficit disorders are at greater risk of developing epilepsy. Comorbid psychiatric disorders have a negative impact on the quality of life of patients with epilepsy. For patients with pharmacoresistant epilepsy, mood disorders are a stronger predictor of a worse perception of their quality of life than is their seizure frequency and severity. Thus, the use of psychotropic drugs is often necessary in patients with epilepsy, be they children or adults. Unfortunately, there are many misconceptions regarding the safety of psychotropic drugs, particularly of antidepressants and central nervous system stimulants, which are often erroneously thought of as being “proconvulsant.” Such misconceptions have resulted in the undertreatment of psychiatric comorbidities in patients with epilepsy. This article provides a practical review of the use of antidepressants, central nervous system stimulants, and antipsychotic drugs in patients with epilepsy.

KEYWORDS

Selective serotonin-reuptake inhibitors - antipsychotic drugs - central nervous system stimulants - mood disorders - attention deficit disorders

REFERENCES

• 1 Tellez-Zenteno J F, Patten S B, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis.  Epilepsia. 2007;  48 2336-2344
• 2 Edeh J, Toone B. Relationship between interictal psychopathology and the type of epilepsy.  Br J Psychiatry. 1987;  151 95-101
• 3 Jacoby A, Baker G A, Steen N et al.. The clinical course of epilepsy and its psychosocial correlates: findings from a UK community study.  Epilepsia. 1996;  37 148-161
• 4 Perini G I, Tosin C, Curraro C et al.. Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy.  J Neurol Neurosurg Psychiatry. 1996;  61 601-605
• 5 Hesdorffer D C, Ludvigsson P, Olafsson E, Gudmundsson G, Kjartansson O, Hauser W A. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children.  Arch Gen Psychiatry. 2004;  61 731-736
• 6 Dominian J, Serafetinides E A, Dewhurst M. A follow-up study of late-onset epilepsy: II. Psychiatric and social findings.  BMJ. 1963;  1 431-435
• 7 Forsgren L, Nystrom L. An incident case referent study of epileptic seizures in adults.  Epilepsy Res. 1990;  6 66-81
• 8 Hesdorffer D C, Hauser W A, Annegers J F et al.. Major depression is a risk factor for seizures in older adults.  Ann Neurol. 2000;  47 246-249
• 9 Hesdorffer D C, Hauser W A, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicidal attempt as risk factor for incidental unprovoked seizures.  Ann Neurol. 2006;  59 35-41
• 10 Austin J K, Harezlak J, Dunn D W et al.. Behavior problems in children before first recognized seizure.  Pediatrics. 2001;  107 115-122
• 11 Jones J E, Watson R, Sheth R et al.. Psychiatric comorbidity in children with new onset epilepsy.  Dev Med Child Neurol. 2007;  49 493-497
• 12 Berg A T, Vickrey B G, Testa F M, Levy S R, Shinnar S, DiMario F. Behavior and social competency in idiopathic and cryptogenic childhood epilepsy.  Dev Med Child Neurol. 2007;  49 487-492
• 13 McAfee A T, Chilcott K E, Johannes C B, Hornbuckle K, Hauser W A, Walker A M. The incidence of first unprovoked seizure in pediatric patients with and without psychiatric diagnsoses.  Epilepsia. 2007;  48 1075-1082
• 14 Alper K, Schwartz K A, Kolts R L, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.  Biol Psychiatry. 2007;  62 345-354
• 15 Kanner A M. Current review in clinical science. Depression in epilepsy: a neurobiologic perspective.  Epilepsy Curr. 2005;  5 21-27
• 16 Lehrner J, Kalchmayr R, Serles W et al.. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients.  Seizure. 1999;  8 88-92
• 17 Perrine K, Hermann B P, Meador K J et al.. The relationship of neuropsychological functioning to quality of life in epilepsy.  Arch Neurol. 1995;  52 997-1003
• 18 Gilliam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement.  Epilepsia. 1997;  38 233-236
• 19 Gilliam F. Optimizing health outcomes in active epilepsy.  Neurology. 2002;  58(suppl 5) S9-S20
• 20 Ettinger A, Reed M, Cramer J. Epilepsy Impact Group . Depression comorbidity in community-based patients with epilepsy or asthma.  Neurology. 2004;  63 1008-1014
• 21 Kanner A M, Gilliam F G, Hermann B, Meador K J. Differential effect of mood and anxiety disorders on the quality of life and perception of adverse events to antiepileptic drugs in patients with epilepsy. Abstracts from the 2007 Annual Meeting of the American Epilepsy Society.  Epilepsia. 2007;  48 1-118
• 22 Cramer J A, Blum D, Fanning K, Reed M. Epilepsy Impact Project Group . The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy.  Epilepsy Behav. 2004;  5 337-342
• 23 Jobe P C, Dailey J W, Wernicke J F. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders.  Crit Rev Neurobiol. 1999;  13 317-356
• 24 Jobe P C, Weber R H. Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). In: Gilliam F, Kanner AM, Sheline YI Neurologic Dysfunction in Depression. London; Taylor & Francis 2007: 121-158
• 25 Polc P, Schneeberger J, Haefely W. Effects of several centrally active drugs on the sleep wakefulness cycle of cats.  Neuropharmacology. 1979;  18 259-267
• 26 Piette Y, Delaunois A L, DeShaepdryver A F, Heymans C. Imipramine and electroshock threshold.  Arch Int Pharmacodyn Ther. 1963;  144 293-297
• 27 Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys.  Pharmacol Biochem Behav. 1980;  12 155-161
• 28 Favale E, Rubino V, Mainardi P, Lunardi G, Albano C. The anticonvulsant effect of fluoxetine in humans.  Neurology. 1995;  45 1926-1927
• 29 Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis.  Seizure. 2003;  12 316-318
• 30 Specchio L M, Iudice A, Specchio N et al.. Citalopram as treatment of depression in patients with epilepsy.  Clin Neuropharmacol. 2004;  27 133-136
• 31 Fromm G H, Wessel H B, Glass J D, Alvin J D, VanHorn G. Imipramine in absence and myoclonic-astatic seizures.  Neurology. 1978;  28 953-957
• 32 Hurst D L. The use of imipramine in minor motor seizures.  Pediatr Neurol. 1986;  2 13-17
• 33 McConnell H, Duncan D. Treatment of psychiatric comorbidity in epilepsy. In: McConnell H, Snyder P Psychiatric Comorbidity in Epilepsy. Washington, DC; American Psychiatric Association Press 1998: 245-362
• 34 Kanner A M, Kozak A M, Frey M. The use of sertraline in patients with epilepsy: is it safe?.  Epilepsy Behav. 2000;  1 100-105
• 35 Ago J, Ishikawa T, Matsumoto N, Ashequr Rahman M, Kamei C. Mechanism of imipramine-induced seizures in amygdala-kindled rats.  Epilepsy Res. 2006;  72 1-9
• 36 Tollefson G D, Rosenbaum J F. Selective serotonin reuptake inhibitors. In: Schatzberg AF, Nemeroff CB Textbook of Psychopharmacology. 2nd ed. Washington, DC; American Psychiatric Association Press 1998: 219-237
• 37 Trimble M R, Mula M. Antiepileptic drug interactions in patients requiring psychiatric drug treatment. In: Majkowski J, Bourgeois B, Patsalos P, Mattson R Antiepileptic Drugs: Combination Therapy and Interactions. Cambridge; Cambridge University Press 2005: 350-368
• 38 McDermott S, Mani S, Krishnaswami S. A population-based analysis of specific behavior problems associated with childhood seizures.  J Epilepsy. 1995;  8 110-118
• 39 Hemmer S A, Pasternak J F, Zecker S G, Trommer B L. Stimulant therapy and seizure risk in children with ADHD.  Pediatr Neurol. 2001;  24 99-102
• 40 Dunn D W, Austin J K, Harezlak J, Ambrosius W T. ADHD and epilepsy in childhood.  Dev Med Child Neurol. 2003;  45 50-54
• 41 Dunn D W, Kronenberger W G. Childhood epilepsy, attention problems, and ADHD: review and practical considerations.  Semin Pediatr Neurol. 2005;  12 222-228
• 42 Feldman H, Crumine P, Handen B L, Alvin R, Teodori J. Methylphenidate in children with seizures and attention-deficit disorder.  Am J Dis Child. 1989;  143 1081-1086
• 43 Gross-Tsur V, Manor O, van der Meere J, Joseph A, Shalev R S. Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?.  J Pediatr. 1997;  130 670-674
• 44 Gonzalez-Heydrich J, Dodds A, Whitney J et al.. Psychiatric disorders and behavioral characteristics of pediatric patients with both epilepsy and attention-deficit hyperactivity disorder.  Epilepsy Behav. 2007;  10 384-388
• 45 Biederman J, Swanson J M, Wigal S B et al.. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.  Pediatrics. 2005;  116 e777-e784
• 46 Greenhill L L, Biederman J, Boellner S W et al.. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder.  J Am Acad Child Adolesc Psychiatry. 2006;  45 503-511
• 47 Swanson J M, Greenhill L L, Lopez L A et al.. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.  J Clin Psychiatry. 2006;  67 137-147
• 48 Rugino T A, Samsock T C. Modafinil in children with attention-deficit/hyperactivity disorder.  Pediatr Neurol. 2003;  29 136-142
• 49 Biederman J, Swanson J M, Wigal S B et al.. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study.  J Clin Psychiatry. 2006;  67 727-735
• 50 Wernicke J F, Holdridge K C, Jin L et al.. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.  Dev Med Child Neurol. 2007;  49 498-502
• 51 Hernández A J, Barragán C. Efficacy of atomoxetine treatment in children with ADHD and epilepsy.  Epilepsia. 2005;  46(suppl 6) 241
• 52 Trimble M R, Schmitz B. The Neuropsychiatry of Epilepsy. Cambridge and New York; Cambridge University Press 2002
• 53 Schmitz B, Wolf P. Psychosis in epilepsy: frequency and risk factors.  J Epilepsy. 1995;  8 295-305
• 54 Stahl S M. Antipsychotic agents. In: Stahl SM Essential Pharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. New York, NY; Cambridge University Press 2000: 401-458
• 55 Logothetis J. Spontaneous epileptic seizures and EEG changes in the course of phenothiazine therapy.  Neurology. 1967;  17 869-877
• 56 Whitworth A B, Fleischhacker W W. Adverse effects of antipsychotic drugs.  Int Clin Psychopharmacol. 1995;  9(suppl 5) 21-27
• 57 Pacia S V, Devinsky O. Clozapine-related seizures: experience with 5,629 patients.  Neurology. 1994;  44 2247-2249
• 58 Tiihonen J, Nousiainen U, Hakola P et al.. EEG abnormalities associated with clozapine treatment [letter].  Am J Psychiatry. 1991;  148 1406